Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649788 | 0.91 | L3MBTL1 (0.46) | L3MBTL1KMT2ATSHRALDH1A1POLB | |
| SCHEMBL10063522 | 0.86 | L3MBTL1 (0.42) | L3MBTL1KMT2ATSHRALDH1A1POLB | |
| SCHEMBL16502101 | 0.85 | USP2 (0.43) | PIK3R1PIK3CAKMT2AALOX15TSHR | |
| SCHEMBL648569 | 0.82 | CYP11B2 (0.41) | PIK3R1PIK3CASMN1; SMN2 | |
| SCHEMBL648675 | 0.80 | GAA (0.41) | L3MBTL1PIK3R1PIK3CATSHRALDH1A1 | |
| SCHEMBL158497 | 0.76 | TSHR (0.55) | L3MBTL1KMT2ATSHRALDH1A1POLB | |
| SCHEMBL10092901 | 0.76 | USP2 (0.45) | KMT2AALOX15TSHRALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL27776511 | 0.74 | TSHR (0.53) | L3MBTL1KMT2ATSHRALDH1A1POLB | |
| SCHEMBL17177194 | 0.74 | TSHR (0.48) | L3MBTL1KMT2AALOX15TSHRALDH1A1 | |
| SCHEMBL3654778 | 0.74 | ALDH1A1 (0.32) | L3MBTL1PIK3R1PIK3CATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2262795-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| EP-2257543-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | AstraZeneca AB (SE) | 2010-12-08 | — | — | EP | disclosed |
| EP-2197843-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | AstraZeneca AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009110844-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | ASTRAZENECA AB (SE) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009108117-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108117-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | CHRM1, CHRM2, CHRM3 | L3MBTL1 3556/4885PIK3R1 2361/4885PIK3CA 2310/4885 |
| US-20090076078-A1 | New compounds 966 | OPRM1, OPRL1, OPRK1 | L3MBTL1 1816/4885PIK3R1 4410/4885PIK3CA 3440/4885 |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | CHRM1, CHRM2, CHRM3 | L3MBTL1 3617/4885PIK3R1 2185/4885PIK3CA 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.